Regeneron shares lower after saying antibody-conveyed immunity may be reduced against omicron variant Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- MEI Pharma (MEIP) up 10% after announcing that the pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma patients who received at least two prior systemic therapies demonstrated a 70.3% objective response rate, or ORR, as determined by Independent Review Committee, or IRC, assessment in the primary efficacy population
UP AFTER EARNINGS -
- Citi Trends (CTRN) up 7%
- Chico's (CHS) up 1%
- RedHill Biopharma (RDHL) up 7%
DOWN AFTER EARNINGS -
- JinkoSolar (JKS) down 6%
- Baozun (BZUN) down 9%
- iClick Interactive Asia (ICLK) down 7%
LOWER -
- Regeneron (REGN) down 2% after saying that prior in vitro analyses and structural modeling regarding the individual mutations present in the omicron variant indicate that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody-conveyed immunity, including the current REGEN-COV antibodies
- Intuit (INTU) down 4% after 1.55M share secondary offering priced at $668.95 per share
Symbols:
MEIP CTRN CHS RDHL JKS BZUN ICLK REGN INTU - $694.14 /
+24.93 (+3.73%)
Keywords: Fly Intel, Wall Street, Top Stories, Stocks